Rethinking Early‑Phase Oversight
Early-phase oversight fails when data is fragmented, and true clinical confidence only comes from seeing signals in full context.
The True Cost of Excel in Subject Review
Excel may feel familiar, but its hidden gaps undermine subject review and create risk long before teams can see it.
Mapping the Oncology Research Landscape
Oncology R&D is evolving through precision, disciplined portfolios and pragmatic AI integration.
Top 10 FDA Warning Letter Findings in Computer System Validation
A deeper look at the recurring FDA warning letter findings that reveal whether your computer system validation is truly under control.
2026 Clinical Trials Reality Check
Clinical trials may look stable on paper but rising rare disease, CNS and cardiovascular complexity is exposing old operating models.
How Voice Data Is Changing Clinical Trials
Speech data is emerging as a new way to track behavioural changes in clinical trials.
Is the UK Clinical Trials Sector Turning a Corner?
The UK’s clinical trials sector is gaining real momentum giving sponsors new confidence to bring studies back.
Risk-Based Quality Management in 2026
2026 marks a turning point for Risk-Based Quality Management as ICH E6(R3) moves from theory to practice.
Integration Is the New Compliance Currency
In 2026, compliance will hinge on RBQM integration, a governance loop that links risk with audit-ready evidence.
When RBQM Pilots Stall
Partial RBQM implementation is a structural weakness that exposes sponsors to risk and regulatory scrutiny.